异常中期细胞遗传学预测骨髓瘤静脉血栓栓塞:PRISM评分推导与验证
在2008至2018年克利夫兰诊所连续诊断的783例骨髓瘤患者中推导PRISM评分,包含既往静脉血栓栓塞、既往手术、免疫调节药物使用、异常中期细胞遗传学和黑人种族5项,模型c统计量为0.622,低、中、高风险12个月累积静脉血栓栓塞发生率分别为2.7%、10.8%和36.5%,外部验证中每增加1分亚分布风险比为1.23。
要点
- PRISM评分包含既往静脉血栓栓塞、既往手术、免疫调节药物使用、异常中期细胞遗传学和黑人种族5项。
- 低、中、高风险组12个月累积静脉血栓栓塞发生率分别为2.7%、10.8%和36.5%。
- 推导队列每增加1分亚分布风险比为1.28,外部验证为1.23。
核心结论
- PRISM评分可指导临床医生识别静脉血栓栓塞高风险患者,但需额外外部验证才能纳入常规临床实践。
研究设计与样本
- 研究为风险预测模型推导与验证,推导队列为2008至2018年在克利夫兰诊所连续诊断且有基线候选危险因素数据的骨髓瘤患者,共783例。
- 主要结局为治疗开始后1年内静脉血栓栓塞(深静脉血栓/肺栓塞)。
- 采用多变量模型,权重由亚分布风险比推导构建风险评分。
- 模型通过内部bootstrap验证和外部验证队列进行验证。
主要发现
- 推导出5项PRISM评分,模型c统计量为0.622(95%CI 0.567-0.674)。
- 模型将患者分为低、中、高风险,12个月累积静脉血栓栓塞发生率分别为2.7%、10.8%和36.5%。
- 推导数据集中每增加1分亚分布风险比为1.28(95%CI 1.19-1.39;P<.001)。
- 外部验证数据集中每增加1分亚分布风险比为1.23(95%CI 1.07-1.41;P=.004)。
关键数值与推荐
- PRISM评分包含以下变量:既往静脉血栓栓塞、既往手术、免疫调节药物使用、异常中期细胞遗传学和黑人种族。
- 低、中、高风险组12个月累积静脉血栓栓塞发生率分别为2.7%、10.8%和36.5%。
- 推导队列每增加1分亚分布风险比为1.28(95%CI 1.19-1.39;P<.001)。
- 外部验证队列每增加1分亚分布风险比为1.23(95%CI 1.07-1.41;P=.004)。
临床怎么用
- PRISM评分可指导临床医生识别静脉血栓栓塞高风险患者。
- 需额外外部验证才能将PRISM评分纳入常规临床实践。
局限性
- 需额外外部验证才能将PRISM评分纳入常规临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although venous thromboembolism (VTE) is an important treatment and disease-related complication in myeloma, a validated risk prediction model including disease-specific variables such as cytogenetics or tumor burden is lacking. The aim of this study was to develop a new risk prediction model for VTE in the context of modern antimyeloma therapy. All consecutive patients diagnosed at the Cleveland Clinic between 2008 and 2018 and with available data on baseline candidate risk factors constituted the derivation cohort. The primary outcome was VTE (deep venous thrombosis/pulmonary embolism) within 1 year of treatment initiation. A multivariable model was used, and weights were derived from subdistribution hazard ratios to construct a risk score. The model was validated both by internal bootstrap validation and in an external validation cohort. The derivation cohort consisted of 783 patients. A 5-component risk prediction tool, named the PRISM score, was developed, including the following variables: prior VTE, prior surgery, immunomodulatory drug use, abnormal metaphase cytogenetics, and Black race. The c-statistic of the model was 0.622 (95% confidence interval [CI], 0.567-0.674). The model stratified patients into low, intermediate, and high risk, with 12-month cumulative VTE incidence of 2.7%, 10.8%, and 36.5%, respectively. Risk of VTE increased significantly with increasing score in both the derivation and the external validation data sets, with a subdistribution hazard ratio per 1-point increase of 1.28 (95% CI, 1.19-1.39; P < .001) and 1.23 (95% CI, 1.07-1.41; P = .004) respectively. Although the PRISM score can guide clinicians in identifying patients at a high risk of VTE, additional external validation is necessary for incorporation into routine clinical practice.
引用
- Chakraborty R, Rybicki L, Wei W, et al. Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score. Blood. 2022. PMID: 35772005. doi:10.1182/blood.2022015727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。